Skip to content

Targovax ASA: Two ONCOS-102 abstracts accepted for ASCO

Oslo, Norway, 28 April 2022 – Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that two ONCOS-102 abstracts have been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago 3-7 June 2022.

The abstracts will be released on the ASCO website 26 May 17:00 CEST ( The posters are scheduled for presentation during the ASCO congress 3 – 7 June 2022.

Poster title:Final survival outcomes and immune biomarker analysis of a randomized, open-label, phase I/II study combining oncolytic adenovirus ONCOS-102 with pemetrexed/cisplatin (P/C) in patients with unresectable malignant pleural mesothelioma (MPM)
Presenter:Dr Santiago Ponce, Medical Oncology, Hospital 12 Octubre, Madrid, Spain
Poster title:Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results
Presenter:Dr Dmitriy Zamarin, Memorial Sloan Kettering Cancer Center, New York, USA


About ASCO

American Society of Clinical Oncology Annual Meeting, ASCO 2022 will be held in McCormick Place, Chicago, Illinois, United States between 03 – 07 June 2022.

The 2022 ASCO Annual Meeting Program will offer presentations on the latest research in cancer care. This year’s program will feature sessions complementing the meeting’s theme: Advancing Equitable Cancer Care Through Innovation.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536

Renate Birkeli, Investor Relations
Phone: +47 922 61 624

Media enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and thereby bring benefit to cancer patients with few available treatment alternatives. Targovax is assessing its product candidates in different cancer indications, including melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. On the back of very encouraging clinical data in several indications, both as monotherapy and in immunotherapy and chemotherapy combinations, the next development step for ONCOS-102 will be to further improve immune activation and clinical response in melanoma patients resistant to PD1 checkpoint blockade.

Building on successful phase 1/2 studies demonstrating clinical benefit and providing deep mechanistic insights, Targovax is expanding its ONCOS program into delivery of circular RNA and targeting KRAS mutant cancers with the aim of establishing a platform for development of a rich pipeline of innovative future immunotherapy product candidates.

Source: Targovax